Policy Cures Research's annual G-FINDER report is the world's most comprehensive survey of R&D funding for neglected infectious diseases that disproportionately affect people in developing countries. The 11th G-FINDER report finds that funding for neglected disease R&D in 2017 reached its highest level ever, exceeding US$3.5 billion. This is up seven percent since 2016, driven primarily by new investments from the United Kingdom, European Commission, Germany and India.
Wherever possible, researchers should not just focus on mosquito behavior when working to eliminate malaria, but must also consider how humans behave at night when the risk of being bitten by an infected mosquito is highest, new findings from the Johns Hopkins Center for Communication Programs (CCP) suggest. CCP is based at the Johns Hopkins Bloomberg School of Public Health.
Screening all hospitalized patients with HIV for tuberculosis using urine tests would improve life expectancy and be cost-effective in Malawi and South Africa, reports an international team of investigators led by Massachusetts General Hospital physicians.
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published Jan. 22 in the open-access journal PLOS Medicine by Eva Harris of the University of California, Berkeley, and colleagues.
Clostridium difficile infection (CDI) is a potentially deadly infection in the large intestine most common in people who need to take antibiotics for a long period of time, particularly in Australia's ageing population. But when doses of a new antibiotic called Ramizol were given to hamsters infected with a lethal dose of the bacteria, a significant proportion of hamsters survived the infection.
The results of clinical trials conducted in Ethiopia by the Drugs for Neglected Diseases initiative (DNDi), in partnership with Médecins Sans Frontières (MSF), the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis (VL), a group of patients who have historically suffered from poor treatment options. The results were published today in PLOS Neglected Tropical Diseases.
Researchers at Queen's University Belfast have developed a highly innovative new enzyme biomarker test that has the potential to indicate diseases and bacterial contamination saving time, money and possibly lives.
Millions of people have contracted Zika and chikungunya virus infections since the outbreaks that have been striking Latin America since 2013. Particularly Zika-related malformations in newborns warrant reliable diagnostics. DZIF scientists from the Charité - Universitätsmedizin Berlin demonstrate the problems with the currently available diagnostics, particularly for Zika virus detection, and develop combined testing methods that have higher reliability.
Coinfection with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) has been observed in at least 35 countries on four continents and requires special case management. Currently, the World Health Organization recommends AmBisome monotherapy for treatment. Now, researchers reporting in PLOS Neglected Tropical Diseases have showed that a combination therapy of AmBisome and miltefosine is more effective.
A type of mosquito that transmits malaria has been detected in Ethiopia for the first time, and the discovery has implications for putting more people at risk for malaria in new regions, according to a study led by a Baylor University researcher.